Stock INFU INFUSYSTEM HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings InfuSystem Holdings, Inc.

Equities

INFU

US45685K1025

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-31 pm EDT 		5-day change 1st Jan Change
7.14 USD +0.99% Intraday chart for InfuSystem Holdings, Inc. -0.14% -32.26%
May. 20 InfuSystem Approves $20 Million Share Buyback Plan -- Shares Rise After Hours MT
May. 20 Tranche Update on InfuSystem Holdings, Inc.'s Equity Buyback Plan announced on June 30, 2021. CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • With an expected P/E ratio at 63 and 20.21 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
INFUSYSTEM HOLDINGS, INC. Stock InfuSystem Holdings, Inc.
-32.26% 152M
C-
ABBOTT LABORATORIES Stock Abbott Laboratories
-7.16% 178B
C+
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.86% 67.04B
A
DEXCOM, INC. Stock DexCom, Inc.
-4.28% 47.24B
B-
CENCORA, INC. Stock Cencora, Inc.
+10.32% 44.62B
B-
HOYA CORPORATION Stock Hoya Corporation
+8.14% 42.5B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+15.76% 29.99B
B
TERUMO CORPORATION Stock Terumo Corporation
+15.53% 25.22B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.88% 24.14B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-5.38% 23.69B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. INFU Stock
  4. Ratings InfuSystem Holdings, Inc.